David J Bearss
Tolero Pharmaceuticals, USA
David J Bearss, PhD, brings a consistent and successful track record of drug discovery and development that spans the last 17 years in both academic and industrial settings. He is an expert in small-molecule drug development and in the use of genetic model systems in drug discovery and has deep experience in translational research focused on drug development and the use of genetic markers to predict drug sensitivity. He served as Chief Scientific Officer at SuperGen overseeing early drug discovery and development and subsequently as Co-Director of the Center for Investigational Therapeutics at the Huntsman Cancer Institute, Associate Professor in the Department of Oncological Sciences at the University of Utah and Associate Professor of Physiology & Developmental Biology at
Brigham Young University. He has published more than 70 manuscripts and book chapters, has over 30 patents issued or pending and has won several awards for his scientific achievements.
Abstract : Sequential treatment of AML patients with alvocidib followed by cytarabine and mitoxantrone is highly effective through a mechanism dependent on MCL1 expression and function